KR870005099A - B형간염 표면 항원의 제조방법 및 신규 dna 단편의 제조방법 - Google Patents

B형간염 표면 항원의 제조방법 및 신규 dna 단편의 제조방법 Download PDF

Info

Publication number
KR870005099A
KR870005099A KR860010018A KR860010018A KR870005099A KR 870005099 A KR870005099 A KR 870005099A KR 860010018 A KR860010018 A KR 860010018A KR 860010018 A KR860010018 A KR 860010018A KR 870005099 A KR870005099 A KR 870005099A
Authority
KR
South Korea
Prior art keywords
dna
dna fragment
coding region
host organism
polypeptide coding
Prior art date
Application number
KR860010018A
Other languages
English (en)
Other versions
KR920004050B1 (ko
Inventor
프리드리히초프 유에르크
밀러 하아폴드 마이클
마이클 크레그 제임즈
고어든 벅호울스 리차드
Original Assignee
제이 이이 휘립프스
휘립프스 피트로오리암 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제이 이이 휘립프스, 휘립프스 피트로오리암 캄파니 filed Critical 제이 이이 휘립프스
Publication of KR870005099A publication Critical patent/KR870005099A/ko
Application granted granted Critical
Publication of KR920004050B1 publication Critical patent/KR920004050B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

내용 없음

Description

B형간염 표면 항원의 제조방법 및 신규 DNA 단편의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피치아(Pichia) 디히드록시아세톤 합성효소 유전자(DAS) 조절지역의 제한지도이다.
제3도는 피치아 p40 유전자 조절지역의 제한지도이다.
제5도는 플라스미드 pBSAG5와 pBSAG5I의 조립에 관한 개요를 제공해준다.

Claims (12)

  1. (1) 하기 (a)와 (b)로 이루어진 DNA 단편, 즉 (a) 폴리펩티드 코우딩 지역의 5'말단에 위치할 경우 메신저 RNA의 전사를 조절할 수 있고, (i)이 DNA 단편을 함유한 숙주 유기체와 접촉하고 있는 배지속의 메탄올 존재, (ii)이 DNA 단편을 함유한 숙주 유기체와 접촉하고 있는 배지속에서의 메탄올 이외의 비-이화 물질 억제 탄소원 존재 및 (iii)이 DNA 단편을 함유한 숙주 유기체를 이화물질 억제 탄소 및 에너지원위에서 배양한 후 그 숙주 유기체와 접촉하고 있는 배지속의 탄소원 기아현상중에서 선택되는 한 가지 조건에 대하여 반응하는 조절지역 및, (b) B형 간염 표면 항원 또는 그 일부를 암호화하는 폴리펩티드 코우딩 지역으로 이루어진 DNA 단편, 또는 (2) 그와같은 DNA 단편과 아울러 박테리아 플라스미드 DNA, 선택성 효모 표식 유전자 및 효모 자율복제 서열로 이루어진 플라스미드로 인하여 형질 전환이 된 효모 균주를 메탄올, 이화물질 비(非)-억제 탄소원, 또는 그 혼합물, 또는 적어도 하나의 이화물질 억제 탄소 및 에너지원으로 이루어진 영향 배지속에서 배양하고, 상기 탄소 및 에너지원이 이화물질 억제 탄소 및 에너지원일 경우에는 그 배양 단계의 생성물에게 탄소원 기아현상의 조건을 가해줌을 특징으로 하는 B형간염 표면항원의 제조방법.
  2. 제1항에 있어서, 상기 DNA 단편이 도면 제2도의 제한지도에 나와 있는 것과 같음을 특징으로 하는 조절지역을 갖고 있는 방법.
  3. 제1항 또는 제2항에 있어서, 상기 DNA 단편에 상기 폴리펩티드 코우딩 지역에 의해서 암호화된 메신저 RNA의 전사 종결 및 폴리아데닐화를 조절할 수 있는, 폴리펩티드 코우딩 지역 아래쪽 DNA 3' 서열이 부착되어 있음을 특징으로 하는 방법.
  4. 제1항 내지 제3항 중 어느 한 항에 있어서, 상기 DNA 단편에 박테리아 플라스미드 DNA, 박테리오파아지 DNA, 효모 플라스미드 DNA, 효모 염색체 DNA 또는 그중 둘 이상으로 부터 유래된 하나 이상의 추가적인 DNA 서열이 부착되어 있음을 특징으로 하는 방법.
  5. 제4항에 있어서, 상기 효모 염색체 DNA가 자율 복제 DNA 서열 및 표식 유전자로 이루어짐을 특징으로 하는 방법.
  6. 제5항에 있어서, 상기 자율복제 서열이 PARS1 또는 PARS2인 방법.
  7. 제1항 내지 제6항 중 어느 한 항에 있어서, 상기 DNA 단편에 첫번째 삽입 DNA 단편, 선택성 표식 유전자 및 두번째 삽입 DNA 단편으로 이루어진 연속배열 DNA가 부착되어 있으며 ; 이에 상기 첫번째 및 두번째 삽입 DNA 단편들은 각각 그 길이가 적어도 약 200뉴클레오티드에 상당하고 또 피치아속에 속한 종의 게놈 DNA 부분과 상동하는 뉴클레오티드 서열을 갖고 있으며 ; 상기 DNA 단편과 상기 표식 유전자는 상기 첫번째 삽입 DNA 단편의 3' 말단과 상기 두번째 삽입 DNA 단편의 5' 말단 사이에 위치하며 ; 상기 첫번째 및 두번째 삽입 DNA 단편들은 피치아의 게놈속에 배향되는 것과 같이 서로에 대하여 배향됨을 특징으로 하는 방법.
  8. 제1항 내지 제7항 중 어느 한 항에 있어서, 상기 폴리펩티드 코우딩 지역이, 필수적으로 아래애 나와 있는 약 700 염기쌍 단편, 또는 그의 아(sub)단위, 또는 그의 변이체나 기능상의 등가물로 이루어져 있는 방법
    5'-GAATTCATGG AGAACATCAC ATCAGGATTC CTAGGACCCC
    TGCTCGTGDT ACAGGCGGGG TTTTTCTTGT TGACAAGAAT
    CCTCACAATA CCGCAGAGDC TATACTCGTG GTGGACTTCT
    CTCAATTTTC TAGGGGGATC TCCCGTGTGT CTTGGCCAAA
    ATTCGCAGTC CCCAACCTCC AATCACTCAC CAACCTCCTG
    TCCTCCAATT TGTCCTGGTT ATGGCTGGAT GTGTCTGCGG
    CGTTTTATCA TATTCCTCTT CATCCTGCTG CTATGCCTCA
    TCTTCTTATT GGTTCTTCTG GATTATCAAG GTATGTTGCC
    CGTTTGTCCT CTAATTCCAG GATCAACAAC AACCAGTACG
    GGACCATGCA AAACCTGCAC GACTCCTGCT CAAGGCAACT
    CTATGTTTCC CTCATGTTGC TGTACAAAAC CTACGGATGG
    AAATTGCACC TGTATTCCCA TCCCATCGTC CTGGGCTTTC
    GCAAAATACC TATGGGAGTG GGCCTCAGTC CGTTTCTCTT
    GGCTCAGTTT ACTAGTGCCA TTTGTTCAGT GGTTCGTAGG
    GCTTTCCCCC ACTGTTTGGC TTTCAGCTAT ATGGATGATG
    TGGTATTGGG GGCCAAGTCT GTACAGCATC GTGAGTCCCT
    TTATACCGCT GTTACCAATT TTCTTTTGTC TCTGGGTATA
    CATTTAAGGC CT-3'
  9. 제1항 내지 제8항 중 어느 한 항에 있어서, 상기 B형 간염 표면항원을 분리하고 정제함을 특징으로 하는 방법.
  10. (a) 폴리펩티드 코우딩 지역의 5' 말단에 위치할 경우 메신저 RNA의 전사를 조절할 수 있으며, (i) 이 DNA 단편을 함유한 숙주 유기체와 접촉하고 있는 배지속의 메탄올 존재 ; (ii)이 DNA 단편을 함유한 숙주 유기체와 접촉하고 있는 배지속에서의 메탄올 이외의 비-이화물질 억제 탄소원 존재 및 (iii) 이 DNA 단편을 함유한 숙주 유기체를 이화물질 억제 탄소 및 에너지원 위에서 배양한 후 그 숙주 유기체와 접촉하고 있는 배지속의 탄소원 기아현상중에서 선택되는 적어도 한가지 조건에 대하여 반응하는 조절지역에다 (b) B형간염 표면항원 또는 그 일부를 암호화하는 폴리펩티드 코우딩 지역에 부착시킴을 특징으로 하는 신규 DNA 단편의 제조 방법.
  11. 제10항에 있어서, 상기 조절지역이 도면 제2도의 제한지도에 나와 있는 것과 같음을 특징으로 하는 방법.
  12. 제10항 또는 제11항에 있어서, 상기 폴리펩티드 코우딩 지역에 의해서 암호화된 메신저 RNA의 전사 종결 및 폴리아데닐화를 조절할 수 있는 DNA 3' 서열을 폴리펩티드 코우딩 지역 아래쪽 DNA에 부착시킴을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860010018A 1985-11-26 1986-11-25 B형 간염 표면 항원 및 신규 dna 단편 및 그의 제조방법 KR920004050B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US801,713 1985-11-26
US06/801,713 US4895800A (en) 1985-11-26 1985-11-26 Yeast production of hepatitis B surface antigen

Publications (2)

Publication Number Publication Date
KR870005099A true KR870005099A (ko) 1987-06-04
KR920004050B1 KR920004050B1 (ko) 1992-05-23

Family

ID=25181867

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010018A KR920004050B1 (ko) 1985-11-26 1986-11-25 B형 간염 표면 항원 및 신규 dna 단편 및 그의 제조방법

Country Status (28)

Country Link
US (1) US4895800A (ko)
EP (1) EP0226846B1 (ko)
JP (1) JPH0763372B2 (ko)
KR (1) KR920004050B1 (ko)
CN (1) CN86107885A (ko)
AT (1) ATE92527T1 (ko)
AU (1) AU583683B2 (ko)
CA (1) CA1285895C (ko)
CS (1) CS276453B6 (ko)
DD (1) DD252614A5 (ko)
DE (1) DE3688831T2 (ko)
DK (1) DK565186A (ko)
EG (1) EG17949A (ko)
ES (1) ES2058055T3 (ko)
FI (1) FI95929C (ko)
HU (1) HUT43112A (ko)
IE (1) IE64519B1 (ko)
IL (1) IL80754A (ko)
IN (1) IN166428B (ko)
MX (1) MX4334A (ko)
NO (1) NO176025C (ko)
NZ (1) NZ218286A (ko)
PH (2) PH25941A (ko)
PL (1) PL152882B1 (ko)
PT (1) PT83819B (ko)
TW (1) TW215457B (ko)
YU (1) YU46031B (ko)
ZA (1) ZA868601B (ko)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777240A (en) * 1984-03-08 1988-10-11 Scripps Clinic And Research Foundation SV40 expression vector containing HBxAg as an expression marker
GB8521496D0 (en) * 1985-08-29 1985-10-02 Ciba Geigy Ag Repressible yeast promoters
US5135868A (en) * 1985-10-25 1992-08-04 Phillips Petroleum Company Cultures of yeast of the genus Pichia altered by site selective genomic modification
US5032516A (en) * 1985-10-25 1991-07-16 Phillips Petroleum Company Pichia pastoris alcohol oxidase II regulatory region
US4683293A (en) * 1986-10-20 1987-07-28 Phillips Petroleum Company Purification of pichia produced lipophilic proteins
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
ATE91304T1 (de) * 1987-02-27 1993-07-15 Merck & Co Inc Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
ES2043808T3 (es) * 1987-03-09 1994-01-01 Merck & Co Inc Purificacion de antigeno superficial de hepatitis b recombinante.
CA1341074C (en) * 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
EP0314240A3 (en) * 1987-10-26 1990-03-28 Merck & Co. Inc. Process for purifying recombinant hepatitis antigens
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
IL90021A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Process for the production of interferon
IL89993A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of the hiv 24kda gag protein in methylotrophic yeasts
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
IL89992A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
NZ228948A (en) * 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
AU4332589A (en) * 1988-09-26 1990-04-18 Salk Institute Biotechnology/Industrial Associates, Inc., The Mixed feed recombinant yeast fermentation
WO1990009434A1 (en) * 1989-02-13 1990-08-23 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of superoxide dismutase in pichia pastoris yeast cells
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
JPH06500470A (ja) * 1990-09-04 1994-01-20 メルク　エンド　カンパニー　インコーポレーテッド メチロトローフ酵母細胞におけるインスリン様成長因子の産生
CU22290A1 (es) * 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
US5268273A (en) * 1990-12-14 1993-12-07 Phillips Petroleum Company Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
WO1992013951A1 (en) * 1991-02-04 1992-08-20 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of human serum albumin in methylotrophic yeast cells
CA2063890C (en) * 1991-03-27 2007-03-13 Masami Miura Mutant aox2 promoter, microorganism carrying same, method of preparation thereof and production of heterologous protein using such microorganism
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
CA2058820C (en) * 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
US5330901A (en) * 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
US5850025A (en) * 1991-09-19 1998-12-15 Sibia Neurosciences, Inc. Protection of plants against plant pathogens
ES2118963T3 (es) 1992-05-23 1998-10-01 Smithkline Beecham Biolog Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
JPH06209763A (ja) * 1993-01-13 1994-08-02 Green Cross Corp:The 変異株
US5863894A (en) * 1995-06-05 1999-01-26 Corvas International, Inc. Nematode-extracted anticoagulant protein
CA2202351A1 (en) * 1994-10-18 1996-04-25 George Phillip Vlasuk Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5872098A (en) * 1995-06-05 1999-02-16 Corvas International, Inc. Nematode-extracted anticoagulant protein
HU225126B1 (en) * 1994-10-18 2006-06-28 Dendreon Corp Nematode-extracted serine protease inhibitors and anticoagulant proteins
US5945275A (en) * 1994-10-18 1999-08-31 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5866543A (en) * 1995-06-05 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
US5716808A (en) * 1995-11-09 1998-02-10 Zymogenetics, Inc. Genetic engineering of pichia methanolica
US5955349A (en) * 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
PT1126876E (pt) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
DE60335602D1 (de) * 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
ATE387494T1 (de) * 2002-12-20 2008-03-15 Hoffmann La Roche Hitzelabile desoxyribonuklease i-varianten
EP1460425A1 (en) * 2003-03-17 2004-09-22 Boehringer Mannheim Gmbh Deglycosylated enzymes for conjugates
DE602004025192D1 (de) * 2003-12-05 2010-03-11 Roche Diagnostics Gmbh Rekombinante Carboxypeptidase B und ihre Aufreinigung
PT1926749E (pt) * 2005-09-14 2011-09-29 Sanofi Aventis Deutschland Clivagem de precursores de insulinas por uma variante de tripsina
EP2397854B1 (en) 2006-03-14 2014-06-04 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
JP4216875B2 (ja) * 2006-09-29 2009-01-28 株式会社東芝 メタノール応答性プロモーター、プロモーターと外来遺伝子を発現可能な様式で連結した融合遺伝子、ベクター、形質転換体、およびタンパク質の生産方法
DK2918598T3 (en) 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
US8877208B2 (en) 2008-05-23 2014-11-04 The Regents Of The University Of Michigan Multivalent nanoemulsion vaccines
EP2324049B1 (en) 2008-08-04 2016-05-25 The Government of the U.S.A. as represented by The Secretary of the dept. of Health & Human Services Membrane proximal region of hiv gp41 anchored to the lipid layer of a virus-like particle vaccine
US8664183B2 (en) 2009-02-27 2014-03-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SPANX-B polypeptides and their use
WO2011047340A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
US9566329B2 (en) 2012-04-06 2017-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, attenuated rubella vector to express vaccine antigens
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
ES2597832T3 (es) 2013-03-08 2017-01-23 Janssen Vaccines & Prevention B.V. Vacuna acelular contra la tosferina
EP3331554B1 (en) 2015-08-03 2022-05-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) * 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
GB2055847A (en) * 1979-07-30 1981-03-11 Bull F G Process for the production of carrier particles
US4769238A (en) * 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4803164A (en) * 1981-08-31 1989-02-07 Genentech, Inc. Preparation of hepatitis b surface antigen in yeast
DE3381619D1 (de) * 1982-08-16 1990-07-05 Chemo Sero Therapeut Res Inst Pendelvektor.
IL69202A (en) * 1982-09-08 1991-08-16 Smith Kline Rit Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
CA1341116C (en) * 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
US4515714A (en) * 1983-03-09 1985-05-07 Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute Method for purification of hepatitis B virus surface antigen
EP0135435A3 (en) * 1983-08-22 1987-03-25 Merck & Co. Inc. Immunogenic hbsag derived from transformed yeast
US4614793A (en) * 1983-10-14 1986-09-30 Merck & Co., Inc. Hepatitis A--subunit antigen
JPS60196185A (ja) * 1984-03-19 1985-10-04 Chemo Sero Therapeut Res Inst 形質転換酵母の培養方法
US4879231A (en) * 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4855231A (en) * 1984-10-30 1989-08-08 Phillips Petroleum Company Regulatory region for heterologous gene expression in yeast
US4837148A (en) * 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
US4882279A (en) * 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia

Also Published As

Publication number Publication date
IE863021L (en) 1987-05-26
JPS62190085A (ja) 1987-08-20
PT83819A (en) 1986-12-01
AU583683B2 (en) 1989-05-04
PL262598A1 (en) 1987-09-21
HUT43112A (en) 1987-09-28
YU46031B (sh) 1992-12-21
FI95929C (fi) 1996-04-10
AU6538486A (en) 1987-05-28
NO176025B (no) 1994-10-10
PL152882B1 (en) 1991-02-28
DK565186A (da) 1987-05-27
EP0226846A1 (en) 1987-07-01
NO864704D0 (no) 1986-11-25
KR920004050B1 (ko) 1992-05-23
TW215457B (ko) 1993-11-01
FI864791A (fi) 1987-05-27
YU201386A (en) 1988-10-31
CA1285895C (en) 1991-07-09
FI95929B (fi) 1995-12-29
DD252614A5 (de) 1987-12-23
IL80754A (en) 1993-03-15
ZA868601B (en) 1987-06-24
DE3688831T2 (de) 1993-11-25
PT83819B (pt) 1988-10-14
FI864791A0 (fi) 1986-11-25
ES2058055T3 (es) 1994-11-01
DE3688831D1 (de) 1993-09-09
NO176025C (no) 1995-01-18
CN86107885A (zh) 1987-09-23
CS864186A3 (en) 1992-01-15
IL80754A0 (en) 1987-02-27
EP0226846B1 (en) 1993-08-04
US4895800A (en) 1990-01-23
IN166428B (ko) 1990-05-05
IE64519B1 (en) 1995-08-09
PH25539A (en) 1991-07-24
DK565186D0 (da) 1986-11-25
PH25941A (en) 1991-12-19
NZ218286A (en) 1991-07-26
MX4334A (es) 1993-12-01
EG17949A (en) 1991-03-30
CS276453B6 (en) 1992-06-17
ATE92527T1 (de) 1993-08-15
JPH0763372B2 (ja) 1995-07-12

Similar Documents

Publication Publication Date Title
KR870005099A (ko) B형간염 표면 항원의 제조방법 및 신규 dna 단편의 제조방법
Oka et al. Replication origin of the Escherichia coli K-12 chromosome: the size and structure of the minimum DNA segment carrying the information for autonomous replication
AU594349B2 (en) New gram-positive expression control sequences
KR870004141A (ko) 피치아속 효모의 자리 선택적 게놈 개조의 방법 및 폴리펩티드 제조방법
Keil et al. Evolutionary conservation of genes coding for meta pathway enzymes within TOL plasmids pWW0 and pWW53
US5633154A (en) Method for location of insertion elements
KR920008186A (ko) 이. 콜라이에서 써머스 아쿠아티커스 dna 폴리머라제의 생산을 증가시키는 방법
Koekman et al. A functional map of the replicator region of the octopine Ti plasmid
Wood et al. Complementation of argG and hisA mutations of Escherichia coli by DNA cloned from the archaebacterium Methanococcus voltae
CN104087610A (zh) 穿梭质粒载体及其构建方法和应用
EP0093611B2 (en) Composite plasmid
Mitsui et al. A novel operon encoding formaldehyde fixation: the ribulose monophosphate pathway in the gram-positive facultative methylotrophic bacterium Mycobacterium gastri MB19
Antelmann et al. A gene at 333 degrees on the Bacillus subtilis chromosome encodes the newly identified sigma B-dependent general stress protein GspA
CN101838663B (zh) 一种大肠杆菌-棒状杆菌穿梭组成型表达载体及其构建方法
US5643790A (en) Plasmid vector and a method for regulation of gene expression using the same
Katsuya et al. Overproduction of transcription termination factor Rho in Escherichia coli
Hansen et al. The genes for the eight subunits of the membrane bound ATP synthase of Escherichia coli
Lindsay et al. Enzyme thermostability is a transformable property between Bacillus spp.
Kaczorek et al. Diphtheria toxin promoter function in Corynebacterium diphtheriae and Escherichia coli
Yamao et al. Evolutionary dynamics of tryptophan tRNAs in Mycoplasma capricolum
Lubinski et al. Mechanism of in vitro synthesis of covalently linked dimeric RNA molecules by the poliovirus replicase
Paul et al. Two ResD-controlled promoters regulate ctaA expression in Bacillus subtilis
Horii et al. Replication of ColE2 and ColE3 plasmids: the regions sufficient for autonomous replication
Sauer et al. Possible function of tRNAACGThr in regulation of solvent formation in Clostridium acetobutylicum
O'Connell et al. Transcriptional organization and regulation of a polycistronic cold shock operon in Sinorhizobium meliloti RM1021 encoding homologs of the Escherichia coli major cold shock gene cspA and ribosomal protein gene rpsU

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1990201001398; APPEAL AGAINST DECISION TO DECLINE REFUSAL

E902 Notification of reason for refusal
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition

Free format text: OPPOSITION NUMBER: 001992001245; OPPOSITION DATE: 19920722

N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
O073 Decision to grant registration after opposition [patent]: decision to grant registration
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050408

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee